New Orleans Sign Advertising Voodoo
What I learnt at the recent AACR annual meeting in New Orleans is that cancer immunotherapy studies are requiring industry to think differently about clinical trial design.
As we move into combination trials of novel/novel combinations, how do we efficiently work out not only that each drug is safe, but in what patients they are likely to be most effective?
Readers who listened to the recent Novel Targets Podcast, “Of Mice and Men” will hear about some of the challenges associated with mouse models and how decisions are made moving into the clinic.
What I learnt from the podcast (and I hope you did too) is that if you are doing an immunotherapy trial in patients, the type of mouse model can really matter when it comes to interpretation of the preclinical data.
In response to a subscriber request, today’s post is about some of the statistical challenges in designing combination immunotherapy trials. To many, statistics is like voodoo, so this post does not go into any maths!
Subscribers can login to read more or you can purchase access by clicking on the blue button below.
This week sees the start of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD.
Given the rapid progress that is taking place in the field of cancer immunotherapy, we’re excited to be flying up to DC to attend the meeting for the first time as part of our conference coverage.
Many of the leading translational scientists in immuno-oncology will be at SITC to discuss the current landscape, challenges and opportunities.
For all the promising results we’ve seen so far, harnessing the body’s immune system to fight cancer is very much a work a progress.
Don’t expect much from SITC on social media, most of the data is likely to be unpublished, which is why you have to go to meetings like SITC, ARVO and AACR in person. An important part of attending is the in-person conversations and connections that take place.
You can download the preliminary program on the SITC 2014 Annual meeting website. There’s also an iphone/android app for those attending.
- Addresses by the 2014 Richard V. Smalley, MD Memorial Award recipient, Giorgio Trinchieri, MD – National Cancer Institute and the Annual Meeting keynote speaker, Olivera J. Finn, PhD – University of Pittsburgh
- News on important initiatives and updates in cancer immunotherapy by key stakeholders in the field
- Workshop on Combination Immunotherapy: Where Do We Go From Here?
- Primer on Tumor Immunology and Cancer Immunotherapy™
- Hot Topic Symposia on Managing Engineered T-Cell Toxicities & Accelerating Tumor Immunity with Agonist Antibodies.
If you haven’t already seen it, this educational video from Roche/Genentech, narrated by Dan Chen MD PhD (Cancer Immunotherapy Franchise Head) is not only educational in discussing the mechanism of action of their anti-PDL1 monoclonal antibody, MPDL3280A, but is highly fun and entertaining to watch. Enjoy!
Sally interviewed Dr Chen at ASCO this year for a blog post from the meeting on “Making a difference in advanced bladder cancer.”
Subscribers, whose support helped fund us to go to SITC for the first time, can login below to read more about the 2014 annual meeting at National Harbor, MD or alternatively, you can purchase access via Tinypass by clicking on the blue icon below.